Plain-English translation of NCT07844148 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new medication called GNR-139 works as well as , a well-known eye injection used to treat wet age-related macular degeneration (a condition that causes vision loss in older adults). Neither you nor your doctors will know which medication you receive. Both are given as injections directly into the eye, and the study will measure whether the new treatment helps preserve vision as effectively as the current standard treatment.
Wet age-related macular degeneration is a serious eye condition that can lead to vision loss. This medication is being developed as a potentially more affordable version of an existing treatment, so researchers want to confirm that it works just as well for patients who have never been treated before.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the new medication (GNR-139) or the established treatment () — neither you nor your doctors will know which one. You will receive injections directly into your eye, starting with a screening visit and then follow-up visits to check how well the treatment is working. The study will measure your vision and take detailed eye images to compare how the two medications perform.
AI-generated summary from trial data · Oct 2, 2026 · Not medical advice
Russia